First-in-Human T1D Vaccine Trial Reports Positive Results
A first-in-human study of the coxsackie B vaccine—made by Breakthrough T1D-funded researchers Drs. Hyoty and Knip—reports positive results.
COVID-19 Vaccine Now Available for Children Ages 5+
Late Tuesday evening, Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC), recommended the use of the Pfizer/BioNTech COVID-19 vaccine in children ages 5–11. This decision followed the FDA’s Emergency Use Authorization on Friday, Oct. 29th. That means that if you have a child 5 years of age or older, they […]
Vertex Shares Data from Their Stem Cell-Derived Therapy—and It’s Outstanding
In February, Vertex announced they were beginning a clinical trial for VX-880, their stem cell-derived therapy for use in people with type 1 diabetes (T1D). Today, they announced that the first person to receive this therapy now needs 91% less insulin 90 days after receiving an infusion of these fully differentiated cells at just half […]
Vertex Pharmaceuticals Investigating Cell Therapy for Type 1 Diabetes
Vertex is currently enrolling for a clinical trial evaluating their stem cell derived islet cell infusion therapy, VX-880.
Teplizumab (the Therapy that Delays T1D By Nearly 3 Years) Isn’t Approved…Yet
The FDA issued a letter to Provention Bio for the use of teplizumab to delay T1D in at-risk individuals, meaning that it has not been approved at this time.
At ADA, Breakthrough T1D-Funded Research Takes Center Stage
There were a number of fantastic results at the ADA’s Scientific Sessions. Here is a video and a summary of the key takeaways from the conference.
Advancing Cures with Type 1 Diabetes Clinical Trials
May 20 is Clinical Trials Day, a day to raise awareness of clinical research and the people around the world who take part in trials.
50+ Years with Type 1: An Interview with Dr. George King
I got the privilege of interviewing George King, M.D., whose research is on diabetes complications. Breakthrough T1D has funded him since he was early in his career.
National DNA Day!
Aaron Michels, M.D., discovered that methyldopa—a therapy that has been used for 50 years to treat high blood pressure—may have a role in delaying T1D.
FDA Breakthrough Therapy Designation for TTP399—A Potential First-in-Class Adjunct Therapy in T1D
The FDA granted Breakthrough Therapy designation for vTv Therapeutics’ TTP399 as an adjunct therapy to insulin for T1D.
